Shaw

Home

About

Stanley Shaw's Lab

Compound selection

The Shaw laboratory seeks to discover novel ways to phenotype patients, particularly through functional assays on patient-derived cells. Our overall goal is to use patient-derived cells to understand how disease alleles affect cellular pathways, and to discover new therapeutic approaches. We utilize a mix of high-throughput screening, wet lab, bioinformatic, and patient-focused approaches. Major areas of research include:

  1. High-throughput chemical screens for functional genomics of disease alleles
  2. Extracting cardiovascular and diabetic phenotypes from Electronic Medical Records (EMRs), and linking clinical phenotypes (diagnoses, outcomes, medications) with genetic and epigenetic data. (A collaboration with the National Center for Biocomputing at Harvard Medical School and i2b2 (Informatics for Integrating Biology and the Bedside)).
  3. Chemical biology of stem cell differentiation and iPS generation
  4. Novel cellular phenotypes from clinical cohorts
  5. Synthesis and characterization of novel nanoparticle molecular imaging probes

Dr. Shaw is Co-Founder and Co-Director of the Center for Assessment Technology and Continuous Health (CATCH),which seeks to develop quantitative phenotypes, digital health tools, and integrative analytics for biomedical discovery. For more information on CATCH, please visit catch-health.org

Recent Publications (more...)

Khor B, Gagnon JD, Goel G, Roche MI, Conway KL, Tran K, Aldrich LN, Sundberg TB, Paterson AM, Mordecai S, Dombkowski D, Schirmer M, Tan PH, Bhan AK, Roychoudhuri R, Restifo NP, O'Shea JJ, Medoff BD, Shamji AF, Schreiber SL, Sharpe AH, Shaw SY, Xavier RJ
The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells.
eLife. 2015;4:ePub - PMID: 25998054 - PMCID: PMC4441007